Malignant Supratentorial Neoplasm
Associated Genetic Biomarkers
Malignant supratentorial neoplasms most frequently harbor alterations in EPHB1, DICER1, CDK12, ATR, and ATM .
EPHB1 V205E, EPHB1 Mutation, CDK12 P1091S, CDK12 Mutation, and ATR Mutation are the most common alterations in malignant supratentorial neoplasm .
There are 3 clinical trials for malignant supratentorial neoplasm, of which 3 are open and 0 are completed or closed. Of the trials that contain malignant supratentorial neoplasm as an inclusion criterion, 1 is early phase 1 (1 open), 1 is phase 1 (1 open), and 1 is phase 2 (1 open).
EGFR and MGMT are the most frequent gene inclusion criteria for malignant supratentorial neoplasm clinical trials .
Osimertinib, temozolomide, and abemaciclib are the most common interventions in malignant supratentorial neoplasm clinical trials.
Significant Genes in Malignant Supratentorial Neoplasm
EGFR is an inclusion eligibility criterion in 1 clinical trial for malignant supratentorial neoplasm, of which 1 is open and 0 are closed. Of the trial that contains EGFR status and malignant supratentorial neoplasm as inclusion criteria, 1 is phase 2 (1 open) .
2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.